Goldman Sachs
CADL icon

Goldman Sachs’s Candel Therapeutics CADL Stock Holding History

Goldman Sachs’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.14M Buy
305,216
+77,695
+34% +$587K ﹤0.01% 4305
2026
Q1 		$1.11M Buy
227,521
+162,436
+250% +$884K ﹤0.01% 5024
2025
Q4 		$368K Buy
65,085
+29,064
+81% +$156K ﹤0.01% 5769
2025
Q3 		$184K Sell
36,021
-43,384
-55% -$251K ﹤0.01% 5973
2025
Q2 		$402K Buy
79,405
+24,739
+45% +$127K ﹤0.01% 5288
2025
Q1 		$309K Sell
54,666
-10,570
-16% -$86.4K ﹤0.01% 5442
2024
Q4 		$566K Buy
65,236
+34,975
+116% +$207K ﹤0.01% 5178
2024
Q3 		$210K Buy
30,261
+12,036
+66% +$74.8K ﹤0.01% 5438
2024
Q2 		$113K Buy
+18,225
New +$137K ﹤0.01% 5389
2022
Q3 		– Sell
-10,037
Closed -$33K – 6281
2022
Q2 		$33K Sell
10,037
-473
-5% -$1.89K ﹤0.01% 6104
2022
Q1 		$53K Sell
10,510
-83
-0.8% -$412 ﹤0.01% 6260
2021
Q4 		$83K Buy
+10,593
New +$103K ﹤0.01% 6173

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's CADL Position: Q2 2026 in Review

Goldman Sachs increased its Candel Therapeutics (CADL) stake by 34% in Q2 2026, buying an estimated $587K and bringing the position to 305,216 shares worth $3.14M. The position accounts for ﹤0.01% of the portfolio, ranked #4305.

Goldman Sachs first reported a position in CADL in Q4 2021 and has held it in 12 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Goldman Sachs held 305,216 shares of Candel Therapeutics worth $3.14M as of Q2 2026.
  • Goldman Sachs bought 77,695 Candel Therapeutics shares in Q2 2026, an estimated $587K.
  • Candel Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4305 holding.
  • Goldman Sachs first reported a position in Candel Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.